82VS, Boston, MA
Developing novel RNA therapeutics for CMT
82VS, the venture studio of Alloy Therapeutics, Inc., is looking to develop novel Antibody Oligonucleotide Conjugate therapeutics for CMT.
Oligonucleotide therapeutics offer promise for treating genetic disorders but have faced challenges as potential drugs for CMT due to limited delivery to the peripheral nerves and affected cell types. Transferrin receptor (TfR1) antibodies have recently been shown to enhance oligonucleotide delivery to muscle, brain, and peripheral nerves. This project by 82VS aims to combine Alloy Therapeutics’ novel TfR1 antibodies with oligonucleotides to improve delivery and efficacy in CMT-relevant tissues. If successful, this approach could enable treatments for all types of CMT.
This partnership between the CMT Research Foundation and 82VS is an innovative approach to tackling Charcot-Marie-Tooth disease. Alloy’s combined expertise in antibody discovery and oligonucleotide development make us uniquely suited to develop these next-generation therapeutic approaches. We’re excited to partner with the patient advocacy expertise of CMTRF to pursue new medicines for CMT patients.
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy